<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 25 Mar 2021 07:28:31 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>胶囊剂溶出度方法及影响因素的探讨</title><link>https://mp.weixin.qq.com/s/Ui-C-sjXnjtXnNYaGg0BlA</link><description></description><content:encoded><![CDATA[胶囊剂溶出度方法及影响因素的探讨]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:25:25 +0800</pubDate></item><item><title>药审中心各类适应症项目管理人员联系方式更新了！</title><link>https://mp.weixin.qq.com/s/bDGccsoms5G9Gb36CapHZw</link><description></description><content:encoded><![CDATA[药审中心各类适应症项目管理人员联系方式更新了！]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:25:25 +0800</pubDate></item><item><title>化学药物生产现场检查问答总结</title><link>https://mp.weixin.qq.com/s/xF-DZ2qyqIS0VmLDoRB_Fg</link><description></description><content:encoded><![CDATA[化学药物生产现场检查问答总结]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:25:25 +0800</pubDate></item><item><title>完善药品专利强制许可实施程序的思考</title><link>https://mp.weixin.qq.com/s/eh71c7x_ga6zWwy_IK0McQ</link><description></description><content:encoded><![CDATA[完善药品专利强制许可实施程序的思考]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:25:25 +0800</pubDate></item><item><title>GMP知识培训课件ppt</title><link>https://mp.weixin.qq.com/s/GXYxs6GhTE5PEOWzawLbvA</link><description></description><content:encoded><![CDATA[GMP知识培训课件ppt]]></content:encoded><pubDate>Tue, 23 Mar 2021 19:57:43 +0800</pubDate></item><item><title>中国抗体药物被哪些技术“卡”住了脖子？</title><link>https://mp.weixin.qq.com/s/s-YhOXWrWulFgl9ZPEXfvg</link><description></description><content:encoded><![CDATA[中国抗体药物被哪些技术“卡”住了脖子？]]></content:encoded><pubDate>Tue, 23 Mar 2021 19:57:43 +0800</pubDate></item><item><title>药学申报资料该附哪些图谱？</title><link>https://mp.weixin.qq.com/s/I4_ptQ8sYMuayhoIejE66Q</link><description></description><content:encoded><![CDATA[药学申报资料该附哪些图谱？]]></content:encoded><pubDate>Tue, 23 Mar 2021 19:57:43 +0800</pubDate></item><item><title>聚焦小分子创新药FIC，罗氏/海思科/恒瑞/交大/复旦...PharmaCon首批嘉宾阵容曝光</title><link>https://mp.weixin.qq.com/s/VLu2g5tRWNpZz1BIEH-teQ</link><description></description><content:encoded><![CDATA[聚焦小分子创新药FIC，罗氏/海思科/恒瑞/交大/复旦...PharmaCon首批嘉宾阵容曝光]]></content:encoded><pubDate>Tue, 23 Mar 2021 19:57:43 +0800</pubDate></item><item><title>FDA培训PPT：海报问答</title><link>https://mp.weixin.qq.com/s/_VPqoo1OyXdIxrJ2aKJDTw</link><description></description><content:encoded><![CDATA[FDA培训PPT：海报问答]]></content:encoded><pubDate>Mon, 22 Mar 2021 19:40:46 +0800</pubDate></item><item><title>选择性PPARγ调节剂的研究新进展</title><link>https://mp.weixin.qq.com/s/DWjyMo3pwQCr1MDBypS6fg</link><description></description><content:encoded><![CDATA[选择性PPARγ调节剂的研究新进展]]></content:encoded><pubDate>Mon, 22 Mar 2021 19:40:46 +0800</pubDate></item><item><title>药品晶型研究及晶型质量控制指导原则及实例介绍（PPT）</title><link>https://mp.weixin.qq.com/s/ui34zJwnEQZf3MylALlikA</link><description></description><content:encoded><![CDATA[药品晶型研究及晶型质量控制指导原则及实例介绍（PPT）]]></content:encoded><pubDate>Mon, 22 Mar 2021 19:40:46 +0800</pubDate></item><item><title>严重副作用不同疾病的对应手册（面向患者·公众）（59）-头痛</title><link>https://mp.weixin.qq.com/s/reP8ZyQyllIGt-GiH3LKNg</link><description></description><content:encoded><![CDATA[严重副作用不同疾病的对应手册（面向患者·公众）（59）-头痛]]></content:encoded><pubDate>Sun, 21 Mar 2021 21:42:35 +0800</pubDate></item><item><title>​FDA 培训PPT：DMF有效沟通策略</title><link>https://mp.weixin.qq.com/s/nGkmJc_lj-pl5HFmNKV3oA</link><description></description><content:encoded><![CDATA[​FDA 培训PPT：DMF有效沟通策略]]></content:encoded><pubDate>Sun, 21 Mar 2021 21:42:35 +0800</pubDate></item><item><title>固体制剂生产工艺及验证要点（62页PPT）</title><link>https://mp.weixin.qq.com/s/K3OX8C9EktXYLsnZprDmLg</link><description></description><content:encoded><![CDATA[固体制剂生产工艺及验证要点（62页PPT）]]></content:encoded><pubDate>Sun, 21 Mar 2021 21:42:35 +0800</pubDate></item><item><title>CHO细胞表达重组单克隆抗体载体的构建策略</title><link>https://mp.weixin.qq.com/s/KLH_01g9PfSvRV8shhEpkg</link><description></description><content:encoded><![CDATA[CHO细胞表达重组单克隆抗体载体的构建策略]]></content:encoded><pubDate>Sun, 21 Mar 2021 21:42:35 +0800</pubDate></item><item><title>化疗无效后的生命奇迹：CAR-T免疫细胞疗法让我的淋巴瘤彻底消失了</title><link>https://mp.weixin.qq.com/s/aZaJrMhO6Hdxy1cav8vzKw</link><description></description><content:encoded><![CDATA[化疗无效后的生命奇迹：CAR-T免疫细胞疗法让我的淋巴瘤彻底消失了]]></content:encoded><pubDate>Sat, 20 Mar 2021 19:05:41 +0800</pubDate></item><item><title>临床期间药学变更报不报？你说了算！</title><link>https://mp.weixin.qq.com/s/QcMaVDR8A_LFzfhEgyJteA</link><description></description><content:encoded><![CDATA[临床期间药学变更报不报？你说了算！]]></content:encoded><pubDate>Sat, 20 Mar 2021 19:05:41 +0800</pubDate></item><item><title>全球ADC简要梳理</title><link>https://mp.weixin.qq.com/s/3KneeapDXGvvkqYpZbB-2A</link><description></description><content:encoded><![CDATA[全球ADC简要梳理]]></content:encoded><pubDate>Sat, 20 Mar 2021 19:05:41 +0800</pubDate></item><item><title>【干货收藏】药用辅料功能性指标对BE的影响——黄原胶 &amp; 枸橼酸（篇）</title><link>https://mp.weixin.qq.com/s/pCNgK2c3OozjwnjrfQnIkw</link><description></description><content:encoded><![CDATA[【干货收藏】药用辅料功能性指标对BE的影响——黄原胶 & 枸橼酸（篇）]]></content:encoded><pubDate>Fri, 19 Mar 2021 21:12:41 +0800</pubDate></item><item><title>浅谈欧洲药品专利期补偿制度的现状和发展趋势</title><link>https://mp.weixin.qq.com/s/H3-ibU3d0U9-oBaoKYh_kA</link><description></description><content:encoded><![CDATA[浅谈欧洲药品专利期补偿制度的现状和发展趋势]]></content:encoded><pubDate>Fri, 19 Mar 2021 21:12:41 +0800</pubDate></item></channel></rss>